Company
Molecular Partners
Molecular Partners has 11 drugs tracked on RxWires: 2 in Phase 2, 3 in Phase 1/2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| ensovibep | Phase 2 | Covid19 |
| MP0317 + Gemcitabine + Cisplatine + Durvalumab | Phase 2 | Advanced Biliary Tract Carcinoma |
| MP0250 | Phase 1/2 | Neoplasms |
| [212Pb]Pb-MP0712 | Phase 1/2 | Large Cell Neuroendocrine Carcinoma |
| MP0250 plus BOR+DEX | Phase 1/2 | Multiple Myeloma in Relapse |
| MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 | Phase 1 | Leukemia |
| MP0112 | Phase 1 | Diabetic Macular Edema |
| MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen) | Phase 1 | Advanced Malignant Solid Tumor |
| MP0274 | Phase 1 | Neoplasms |
| MP0310 | Phase 1 | Advanced Solid Tumor |
| MP0250 DARPin® drug candidate, Osimertinib | Phase 1 | EGFR-mutated NSCLC (Disorder) |
Latest
No recent events.
Follow Molecular Partners on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.